Checkpoint Therapeutics I... (CKPT)
Checkpoint Therapeutics Statistics
Share Statistics
Checkpoint Therapeutics has 86.32M shares outstanding. The number of shares has increased by 33.15% in one year.
| Shares Outstanding | 86.32M |
| Shares Change (YoY) | 33.15% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 25.62% |
| Shares Floating | 64.48M |
| Failed to Deliver (FTD) Shares | 1.39K |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 5.03M, so 6% of the outstanding shares have been sold short.
| Short Interest | 5.03M |
| Short % of Shares Out | 6% |
| Short % of Float | 6.52% |
| Short Ratio (days to cover) | 3.13 |
Valuation Ratios
The PE ratio is -2.26 and the forward PE ratio is 4.39. Checkpoint Therapeutics's PEG ratio is 0.05.
| PE Ratio | -2.26 |
| Forward PE | 4.39 |
| PS Ratio | 3096.54 |
| Forward PS | 0.7 |
| PB Ratio | -10.06 |
| P/FCF Ratio | -4.08 |
| PEG Ratio | 0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Checkpoint Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.37, with a Debt / Equity ratio of 0.
| Current Ratio | 0.37 |
| Quick Ratio | 0.37 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.71K |
| Profits Per Employee | $-2.34M |
| Employee Count | 24 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 180.56% in the last 52 weeks. The beta is 1.22, so Checkpoint Therapeutics's price volatility has been higher than the market average.
| Beta | 1.22 |
| 52-Week Price Change | 180.56% |
| 50-Day Moving Average | 3.63 |
| 200-Day Moving Average | 3.1 |
| Relative Strength Index (RSI) | 63.62 |
| Average Volume (20 Days) | 2.66M |
Income Statement
In the last 12 months, Checkpoint Therapeutics had revenue of 41K and earned -56.24M in profits. Earnings per share was -1.42.
| Revenue | 41K |
| Gross Profit | 41K |
| Operating Income | -56.17M |
| Net Income | -56.24M |
| EBITDA | -56.17M |
| EBIT | -56.17M |
| Earnings Per Share (EPS) | -1.42 |
Balance Sheet
The company has 6.6M in cash and 0 in debt, giving a net cash position of 6.6M.
| Cash & Cash Equivalents | 6.6M |
| Total Debt | 0 |
| Net Cash | 6.6M |
| Retained Earnings | -370.57M |
| Total Assets | 7.47M |
| Working Capital | -12.63M |
Cash Flow
In the last 12 months, operating cash flow was -31.1M and capital expenditures 0, giving a free cash flow of -31.1M.
| Operating Cash Flow | -31.1M |
| Capital Expenditures | 0 |
| Free Cash Flow | -31.1M |
| FCF Per Share | -0.78 |
Margins
Gross margin is 100%, with operating and profit margins of -137009.76% and -137170.73%.
| Gross Margin | 100% |
| Operating Margin | -137009.76% |
| Pretax Margin | -137170.73% |
| Profit Margin | -137170.73% |
| EBITDA Margin | -137009.76% |
| EBIT Margin | -137009.76% |
| FCF Margin | -75856.1% |
Dividends & Yields
CKPT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CKPT is $4.1, which is 1.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $4.1 |
| Price Target Difference | 1.5% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Dec 6, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Dec 6, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -85.88 |
| Piotroski F-Score | 3 |